ULK1 drives NDP52-mediated selective autophagic degradation of MHC-I to promote immune evasion in HPV-positive head and neck cancer

In HPV-positive head and neck cancer, the ULK1 complex drives the selective autophagic degradation of MARCHF8-ubiquitinated MHC-I via the cargo receptor NDP52, a mechanism that facilitates immune evasion and tumor growth which can be reversed by inhibiting autophagy initiation to restore CD8+ T cell-mediated antitumor responses.

The Gist

The Big Picture: A "Hide and Seek" Game Gone Wrong

Imagine your body is a city, and your immune system (specifically the CD8+ T-cells) is the police force. Their job is to patrol the streets, look for criminals (cancer cells), and arrest them.

To do this, the police need to see the criminals' "Wanted Posters." In our bodies, these posters are called MHC-I proteins. They stick to the surface of every cell and display a tiny flag saying, "I am healthy" or "I am infected/cancerous."

The Problem: In HPV-positive head and neck cancer, the cancer cells are playing a very sneaky game of hide-and-seek. They are tearing down their own "Wanted Posters" (MHC-I) so the police can't see them. Because the police can't see the criminals, the cancer grows unchecked, and treatments that rely on the immune system (like checkpoint inhibitors) often fail.

The Villain: The "Shredder" Machine

The researchers discovered how the cancer cells are hiding.

1. The Tag: First, a viral protein (from the HPV virus) tells the cancer cell to attach a "shred me" tag (ubiquitin) to the Wanted Posters.
2. The Shredder: Usually, cells have a machine called the Proteasome that eats tagged proteins. But in this specific cancer, the proteasome isn't the main culprit.
3. The Real Culprit: The cancer uses a different machine called Autophagy. Think of Autophagy as the cell's internal recycling center. It builds little trash bags (autophagosomes) to swallow up old or damaged parts of the cell and recycle them.

The cancer cell hijacks this recycling center. It uses a specific "recycling manager" protein called NDP52 to grab the tagged Wanted Posters and stuff them into the trash bags. Then, it sends them to the "incinerator" (the lysosome) to be destroyed.

The Result: The cancer cell surface becomes blank. The police (T-cells) walk right past the cancer, thinking it's a normal, healthy citizen.

The Discovery: Finding the "Start Button"

The researchers wanted to stop this shredding process. They performed a massive "genetic screen" (like checking every single switch in a giant control room) to see which genes were helping the cancer hide its posters.

They found that the ULK1 protein is the Start Button for the recycling machine.

• The Analogy: Imagine the recycling machine is a complex factory.
  • ULK1 is the foreman who flips the switch to start the assembly line.
  • NDP52 is the worker who grabs the trash and puts it on the belt.
  • The Lysosome is the incinerator at the end of the line.

The researchers found that if you break the Start Button (ULK1), the whole factory stops before it even begins. The trash bags never get built, and the Wanted Posters stay stuck on the wall where they belong.

Interestingly, if you try to stop the machine later (like blocking the incinerator), it doesn't work. The trash bags have already been built and the posters are already inside. You have to stop the process at the very beginning.

The Solution: Turning the Lights Back On

The team tested this idea in two ways:

1. Genetic Knockout: They genetically removed the ULK1 gene from cancer cells.
   • Result: The cancer cells suddenly had their "Wanted Posters" back on their surface.
2. Drug Treatment: They used a drug called ULK-101 that acts like a wrench thrown into the Start Button.
   • Result: Just like the genetic removal, the drug stopped the recycling, and the posters reappeared.

The Victory: The Police Return

When they injected these "re-armed" cancer cells (with the Start Button broken) into mice, something amazing happened:

• The Police Saw the Criminals: Because the Wanted Posters were back, the CD8+ T-cells (the police) could finally identify the cancer.
• The Attack: The T-cells attacked and killed the cancer cells.
• The Outcome: The tumors stopped growing, and in many cases, the mice were completely cured.

Why This Matters

This is a game-changer for treating HPV-positive head and neck cancer.

• Current Struggle: Many patients get immunotherapy drugs (like Keytruda), but they don't work well because the cancer is hiding its identity.
• New Hope: This study suggests that if we give patients a drug that blocks the ULK1 Start Button, we can force the cancer to reveal itself. Once the cancer is visible, the patient's own immune system (or the immunotherapy drugs) can finish the job.

In short: The cancer was hiding in the dark by shredding its ID cards. This research found the switch that turns the lights back on, allowing the immune system to finally see and destroy the enemy.

Technical Summary

1. Problem Statement

Human Papillomavirus (HPV)-positive head and neck cancers (HPV+ HNC) often exhibit poor responses to immune checkpoint inhibitor (ICI) therapies, despite having high levels of tumor-infiltrating T cells and PD-L1 expression compared to HPV-negative tumors. A primary mechanism of immune evasion in these cancers is the downregulation of Major Histocompatibility Complex Class I (MHC-I) molecules on the tumor cell surface, which prevents CD8+ T cells from recognizing and killing the tumor.

Previous research established that HPV oncoproteins induce the expression of the E3 ubiquitin ligase MARCHF8, which ubiquitinates MHC-I proteins, targeting them for degradation. However, the specific downstream mechanism by which ubiquitinated MHC-I is degraded remained unknown. While autophagy is known to degrade cellular components, it was unclear if it played a role in MHC-I loss in HPV+ HNC, and if so, which specific steps of the autophagy pathway were involved.

2. Methodology

The study employed a multi-faceted approach combining genomic screening, molecular biology, pharmacological inhibition, and in vivo models:

• Genome-wide CRISPR/Cas9 Screens: The researchers performed loss-of-function screens using the Brunello sgRNA library in two HPV+ HNC cell lines (SCC90 and SCC152). Cells were sorted into "MHC-I-low" and "MHC-I-high" populations based on surface expression. sgRNA abundance was quantified via deep sequencing and analyzed using the MAGeCK algorithm to identify negative regulators of MHC-I.
• Genetic Validation: Specific genes identified in the screen (components of ULK1, PIK3C3, and autophagy receptors) were individually knocked out in HPV+ HNC cells using CRISPR/Cas9.
• Pharmacological Inhibition: Cells were treated with specific inhibitors to dissect autophagy stages:
  • ULK-101: Inhibits autophagy initiation (ULK1/2 kinase).
  • Bafilomycin A1 (BafA1) & Chloroquine (CQ): Inhibit post-initiation steps (lysosomal degradation/fusion).
  • MG132: Proteasome inhibitor (control).
• Protein Interaction & Localization:
  • Co-Immunoprecipitation (Co-IP): To identify which selective autophagy receptors (SARs) bind ubiquitinated MHC-I.
  • Immunofluorescence/Confocal Microscopy: To visualize co-localization of MHC-I with ER markers (calreticulin), autophagosome markers (LC3B-GFP), and SARs (NDP52, p62, NBR1).
• In Vivo Models:
  • Generated Ulk1-knockout mouse oral epithelial cells (mEERL) expressing HPV E6/E7 and mutant H-Ras.
  • Subcutaneously injected these cells into C57BL/6J mice to monitor tumor growth and survival.
  • Performed immune profiling (flow cytometry) of tumor tissues and tumor-draining lymph nodes (TDLNs).
• Functional Assays:
  • LDH Release Assay: To measure CD8+ T cell-mediated cytotoxicity.
  • ELISA/ELISpot: To quantify IFN-γ production by CD8+ T cells.

3. Key Contributions

• Identification of Autophagy Initiation as the Critical Step: The study definitively identifies that autophagy initiation (mediated by the ULK1 and PIK3C3 complexes), rather than later stages like autophagosome formation or lysosomal fusion, is the rate-limiting step for MHC-I degradation in HPV+ HNC.
• Discovery of NDP52 as the Specific Cargo Receptor: The authors identified NDP52 (Nuclear Dot Protein 52) as the specific selective autophagy receptor (SAR) that recognizes MARCHF8-ubiquitinated MHC-I and recruits it to autophagosomes.
• Mechanistic Link between HPV and Immune Evasion: The paper elucidates a complete pathway: HPV $\rightarrow$ MARCHF8 upregulation $\rightarrow$ MHC-I ubiquitination (likely K27/K29 chains) $\rightarrow$ NDP52 recognition $\rightarrow$ ULK1-mediated autophagy initiation $\rightarrow$ MHC-I degradation.
• Therapeutic Strategy: Demonstrates that inhibiting the initiation of autophagy (specifically via ULK1) restores MHC-I surface expression and sensitizes tumors to CD8+ T cell killing, offering a novel therapeutic target for HPV+ HNC.

4. Key Results

• Discrepancy in mRNA vs. Protein: While HLA-A/B/C mRNA levels were upregulated in HPV+ HNC patient tumors, protein levels were significantly downregulated, confirming post-transcriptional degradation.
• CRISPR Screen Findings: The screen identified components of the ULK1 complex (ULK1, ULK2, RB1CC1, ATG13) and PIK3C3 complex (BECN1, ATG14) as top negative regulators of MHC-I.
• Initiation vs. Post-Initiation:
  • Knocking out ULK1 or PIK3C3 components significantly increased surface MHC-I.
  • Knocking out ATG5 or ATG7 (required for autophagosome elongation) increased total MHC-I but failed to restore surface MHC-I.
  • Pharmacological inhibition with ULK-101 restored surface MHC-I, whereas BafA1 (lysosomal inhibitor) increased total MHC-I but not surface levels. This indicates MHC-I is diverted to autophagosomes before they can be blocked by lysosomal inhibitors.
• NDP52 Specificity:
  • Knockout of NDP52 (but not p62 or NBR1) restored surface MHC-I.
  • Co-IP confirmed direct binding between MHC-I and NDP52.
  • Confocal microscopy showed high co-localization of MHC-I and NDP52, which was reduced upon MARCHF8 knockdown.
  • MARCHF8 knockdown increased MHC-I localization in the ER and decreased localization in autophagosomes, suggesting MARCHF8 directs MHC-I from the ER to autophagosomes via NDP52.
• In Vivo Efficacy:
  • Tumor Suppression: Ulk1 knockout in mouse HPV+ HNC cells resulted in complete tumor regression or failure to grow in the majority of mice, whereas control tumors grew rapidly.
  • Immune Activation: Ulk1 knockout tumors showed increased infiltration of CD8+ T cells and macrophages.
  • T Cell Function: CD8+ T cells primed with Ulk1-knockout tumor cells exhibited significantly enhanced cytotoxicity (LDH release) and IFN-γ production against wild-type tumor cells.

5. Significance

This study provides a critical mechanistic explanation for the failure of ICI therapy in HPV+ HNC: the virus actively degrades the antigen presentation machinery (MHC-I) via a specific autophagy pathway.

• Clinical Implication: The findings suggest that ULK1 inhibitors (such as ULK-101) could be a promising therapeutic strategy. By blocking the initiation of autophagy, these drugs could "re-expose" tumor antigens to the immune system, potentially converting "cold" tumors into "hot" tumors and restoring sensitivity to checkpoint inhibitors.
• Novel Biology: It highlights a specific, cancer-type-dependent mechanism where NDP52 mediates the degradation of MHC-I, distinct from other cancers where NBR1 or IRGQ might be involved.
• Future Directions: The study opens avenues for combination therapies targeting autophagy initiation alongside immunotherapy to overcome resistance in HPV-driven malignancies.